期刊文献+

TG2在胃癌组织中表达的临床意义 被引量:3

Clinical significance of expression of tissue transglutaminase 2 in gastric carcinoma
下载PDF
导出
摘要 目的:了解组织型转谷氨酰胺酶2(tissue transglutaminase 2,TG2)在胃中的表达情况及其临床意义,为寻找早期诊断胃癌相关的分子标志物提供实验依据.方法:采用RT-PCR和Western blot检测TG2在胃癌组织中的表达;应用免疫组织化学染色检测TG2在胃癌组织中的表达,并分析其在胃癌组织中表达的临床病理学意义.结果:(1)RT-PCR和Western blot结果均显示,TG2在正常胃黏膜和胃癌组织中的表达强度分别为0.274±0.051 vs 0.671±0.105和0.317±0.032 vs 0.918±0.117,与正常胃黏膜组织比较,TG2在胃癌组织中的表达明显增加(P<0.05);(2)免疫组织化学染色结果显示,TG2蛋白在正常胃黏膜和胃癌组织中的阳性表达率分别为33.33%(8/24)和71.74%(33/46),胃癌组织中的阳性表达率明显高于正常胃黏膜组织(P<0.05).结论:TG2蛋白高表达与胃癌的发生密切相关. AIM: To assess the clinical significance of expres- sion of tissue transglutaminase 2 (TG2) in gastric carcinoma, so as to provide a new clue for finding new specific markers of gastric cancer. METHODS: The expression of TG2 in gastric cancer tissues was detected by RT-PCR, Western blot and immunohistochemistry. The clinical significance of TG2 expression in gastric cancer was analyzed. RESULTS: The result of RT-PCR and Western blot analyses showed that the mRNA and pro- tein expression levels of TG2 were significantly lower in normal gastric mucosa than in gastric cancer tissues (0.274 ± 0.051 vs 0.671 ± 0.105, 0.317 ±0.032 vs 0.918 ± 0.117, both P 〈 0.05). The im- munohistochemical results demonstrated that the positive expression rate of TG2 protein in normal gastric mucosa was significantly lower than that in gastric cancer tissues [33.33% (8/24) vs 71.74% (33/46), P 〈 0.05]. CONCLUSION: Overexpression of TG2 protein may be closely related to the occurrence of gas- tric cancer.
出处 《世界华人消化杂志》 CAS 北大核心 2013年第34期3858-3862,共5页 World Chinese Journal of Digestology
基金 湖南省自然科学衡阳联合基金资助项目 No.12JJ9033 湖南省自然科学基金资助项目 Nos.12JJ3102 13JJ3079 湖南省科技厅基金资助项目 Nos.2013SK3118 2011SK3089 湖南省高校创新平台开放基金资助项目 Nos.10K052 12K094 13K082 13K083 湖南省研究生科研创新基金资助项目 No.CX2010B380 湖南省教育厅科研基金资助项目 Nos.11C1112 12C0340~~
关键词 胃癌 TG2 蛋白表达 临床病理 Gastric cancer Tissue transglutami-nase2 Proteic expression Clinical pathology
  • 相关文献

参考文献1

二级参考文献10

  • 1Bray F, Parkin DM, Evaluation of data quality in the cancer registry: Principles and methods. Part I : Comparability, validity and timeliness [J]. Eur J Cancer, 2009, 45(5): 747-755.
  • 2Curado MP, Edwards B, Shin HR et al. Cancer incidence in five conti- nents, Vol. IX. IARC scientific publications No. 160[M]. Lyon: IARC, 2007.
  • 3Parkin DM, Chen VW, Ferlay J, et al. Comparability and quality control in cancer registration. IAtlC technical report No.19[M]. Lyon: IARC. 1994.
  • 4Felay J, Burkhard C, Whelan S, et al. Check and conversion programs for cancer registries. IARC technical report No.42[M]. Lyon: IARC, 2005.
  • 5Felay J. The IARCcrgTools program [CP/OL]. http://www.iaer.com.fr/iarc- crgtools.htm, 2006.
  • 6全国肿瘤登记中心.中国肿瘤登记工作指导手册[M].北京:中国协和医科大学出版社,2004.48-50.
  • 7陈万青,张思维.中国肿瘤登记的代表性研究[J].中国肿瘤,2008,17(10):832-835. 被引量:12
  • 8陈万青,赵平,饶克勤,孔灵芝,胡建平.健全我国肿瘤登记系统[J].中华预防医学杂志,2010,44(5):374-375. 被引量:12
  • 9张思维,雷正龙,李光琳,邹小农,赵平,陈万青.中国肿瘤登记地区2006年肿瘤发病和死亡资料分析[J].中国肿瘤,2010,19(6):356-365. 被引量:192
  • 10陈建国.癌症登记资料的质量评价[J].中国肿瘤,1999,8(3):100-104. 被引量:38

共引文献328

同被引文献29

  • 1Jin-Hong Luo,Jun Zhou,Yong Gao.Correlation between periostin and SNCG and esophageal cancer invasion,infiltration and apoptosis[J].Asian Pacific Journal of Tropical Medicine,2013,6(7):516-519. 被引量:6
  • 2Cappellani A, Zanghi A, Di Vita M, Zanet E, Veroux P, Cacopardo B, Cavallaro A, Piccolo G, Lo Menzo E, Murabito P, Berretta M. Clinical and biological markers in gastric cancer: update and perspec- tives. Front Biosci (Schol Ed) 2010; 2:403-412 [PMID: 20036956].
  • 3Bai Z, Ye Y, Liang B, Xu F, Zhang H, Zhang Y, Peng J, Shen D, Cui Z, Zhang Z, Wang S. Proteomics-based identification of a group of apoptosis-related pro- teins and biomarkers in gastric cancer. Int J Oncol 2011; 38:375-383 [PMID: 21165559 DOI: 10.3892/ ijo.2010.873].
  • 4Bosco R, Melloni E, Celeghini C, Rimondi E, Vac- carezza M, Zauli G. Fine tuning of protein kinase C (PKC) isoforms in cancer: shortening the distance from the laboratory to the bedside. Mini Rev Med Chem 2011; 11:185-199 [PMID: 21534929].
  • 5Redden JM, Le AV, Singh A, Federkiewicz K, Smith S, Dodge-Kafka KL. Spatiotemporal regulation of PKC via interactions with AKAP7 isoforms. Biochem J 2012; 446:301-309 [PMID: 22670899 DOh 10.1042/ BJ20120366].
  • 6Farah CA, Sossin WS. The role of C2 domains in PKC signaling. Adv Exp Med Biol 2012; 740:663-683 [PMID: 22453964 DOI: 10.1007/978-94-007-2888-2_2 9].
  • 7Chen T, Cao L, Dong W, Luo P, Liu W, Qu Y, Fei Z. Protective effects of mGluR5 positive modulators against traumatic neuronal injury through PKC- dependent activation of MEK/ERK pathway. Neu- rochem Res 2012; 37:983-990 [PMID: 22228200 DOh 10.1007/sl1064-011-0691-z].
  • 8Lai KC, Huang AC, Hsu SC, Kuo CL, Yang JS, Wu SH, Chung JG. Benzyl isothiocyanate (BITC) inhib- its migration and invasion of human colon cancer HT29 cells by inhibiting matrix metalloprotein- ase-2/-9 and urokinase plasminogen (uPA) through PKC and MAPK signaling pathway. J Agric Food Chem 2010; 58:2935-2942 [PMID: 20136087 DOI: 10.1021/jf9036694].
  • 9Li L, She H, Yue S, Feng D, Luo Z. Vasoactive intestinal peptide induces surfactant protein A expression in ATII cells through activation of PKC/ c-Fos pathway. Peptides 2010; 31:2046-2051 [PMID: 20688121 DOI: 10.1016/j.peptides.2010.07.017].
  • 10Reddy TR, Li C, Guo X, Myrvang HK, Fischer PM, Dekker LV. Design, synthesis, and structure- activity relationship exploration of 1-substituted 4-aroyl-3-hydroxy-5-phenyl-lH-pyrrol-2(5H)-one analogues as inhibitors of the annexin A2-S100A10 protein interaction. J Med Chem 2011; 54:2080-2094 [PMID: 21375334 DOI: 10.1021/jm101212e].

引证文献3

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部